Continue reading Five Stocks That Prove the China Boom Isn't Over

Five Stocks That Prove the China Boom Isn't Over originally appeared on BloggingStocks on Fri, 26 Mar 2010 17:20:00 EST. Please see our terms for use of feeds.

Just last week General Electric (GE) surged on news that it will likely boost its dividend by some time in 2011. Coupled with the resumption of General Electric's buyback plan, shares set a new 52-week high.

But before you set off the fireworks and jump back into GE with the rest of the lemmings on Wall Street, take a closer look at the stock's fundamentals. My analysis of this company shows some serious flaws in profits and sales growth. Wall Street has forecast negative revenue growth for each of the next four quarters, and though earnings have topped the Street's low expectations recently, they have been relatively flat. That means GE isn't sinking, but it sure isn't going anywhere.

Continue reading GE vs. H.J. Heinz: Which Is the Tastier Dividend Play?

GE vs. H.J. Heinz: Which Is the Tastier Dividend Play? originally appeared on BloggingStocks on Tue, 23 Mar 2010 17:00:00 EST. Please see our terms for use of feeds.

China Green Agriculture (CGA) is an innovative agricultural company that helps farmers grow more crops without hurting the environment. The "green" fertilizer market in China is booming right now due to the fact that the country's population continues to grow alongside its economy. This means that more arable land is needed in the coming years to ensure that there's enough food available to sustain China's growing middle class.

CGA is a small foreign company without much of an analyst following, but you don't need estimates to see how great this pick is.

Continue reading Small Cap #4: China Green Agriculture (CGA)

Small Cap #4: China Green Agriculture (CGA) originally appeared on BloggingStocks on Sun, 07 Mar 2010 11:00:00 EST. Please see our terms for use of feeds.

Continue reading Serious Money: Still Cheap Market -- 35 Stocks + Yields & Growth

Serious Money: Still Cheap Market -- 35 Stocks + Yields & Growth originally appeared on BloggingStocks on Mon, 01 Feb 2010 14:50:00 EST. Please see our terms for use of feeds.

Many retail investors have been shrieking as General Electric (GE) hovers around ten year lows and has gone nowhere all year while almost everything else has appreciated. GE is on hot lists and not lists for 2010.

It is one of my holdover picks from 2009 and if it does not improve in the next few days will be my only loser -- for the other, a winner, see: Chasing Value: 2010 -- #3 EZCORP.

Continue reading Chasing Value: 2010 -- #6 General Electric

Chasing Value: 2010 -- #6 General Electric originally appeared on BloggingStocks on Wed, 30 Dec 2009 15:30:00 EST. Please see our terms for use of feeds.

Continue reading Chasing Value: 2010 -- #3 EZCORP

Chasing Value: 2010 -- #3 EZCORP originally appeared on BloggingStocks on Tue, 29 Dec 2009 18:00:00 EST. Please see our terms for use of feeds.

Real bargain stock #9: Google (GOOG) originally appeared on BloggingStocks on Sun, 04 Oct 2009 12:00:00 EST. Please see our terms for use of feeds.

Continue reading GE is in an uptrend

GE is in an uptrend originally appeared on BloggingStocks on Thu, 24 Sep 2009 15:00:00 EST. Please see our terms for use of feeds.

Continue reading Goodyear Tire's uptrend is clear

Goodyear Tire's uptrend is clear originally appeared on BloggingStocks on Fri, 11 Sep 2009 14:40:00 EST. Please see our terms for use of feeds.

Continue reading Kohl's: Back up the truck

Kohl's: Back up the truck originally appeared on BloggingStocks on Tue, 25 Aug 2009 15:30:00 EST. Please see our terms for use of feeds.

Continue reading Valero Energy has underperformed, but stick with the refiner

Valero Energy has underperformed, but stick with the refiner originally appeared on BloggingStocks on Fri, 14 Aug 2009 14:00:00 EST. Please see our terms for use of feeds.

Continue reading Kellogg: The right products for the 'frugal consumer' era

Kellogg: The right products for the 'frugal consumer' era originally appeared on BloggingStocks on Thu, 13 Aug 2009 16:20:00 EST. Please see our terms for use of feeds.

If you managed to establish a position in FedEx (NYSE: FDX) in April, you're up about 30%, which is not bad, given current economic conditions.

To be sure, FDX is not as cheap as it was then, but I'm still Reiterating my Buy rating for the company, first recommended on April 13, 2009 at a price of $50.98. Here's why:

Continue reading FedEx: In-sync with the U.S. recovery

FedEx: In-sync with the U.S. recovery originally appeared on BloggingStocks on Tue, 11 Aug 2009 15:00:00 EST. Please see our terms for use of feeds.

This was a complex call, but I'm Reiterating my Buy rating for AutoZone (NYSE: AZO), first recommended on March 30, 2009 at a price of $163.40.

Continue reading AutoZone: Auto parts must show results, or else

AutoZone: Auto parts must show results, or else originally appeared on BloggingStocks on Thu, 30 Jul 2009 15:40:00 EST. Please see our terms for use of feeds.

Continue reading Suntech: A worthy solar play

Suntech: A worthy solar play originally appeared on BloggingStocks on Tue, 28 Jul 2009 13:50:00 EST. Please see our terms for use of feeds.

Do you think we're going to see more or less genomics research in coming years? End of discussion.

Illumina (NASDAQ: ILMN) is the leading provider of equipment for genomics researchers and its lead is growing. Buy and hold may be almost dead, but it certainly applies to ILMN. The stock has been trashed along with the market, but it's simply the best at what it does - and getting better.

Your best strategy for life-changing profits?

This is a stock to buy for the long term to use as a base for selling calls. Or, even better, you can write some credit spreads, as the calls have terrific premiums.

Don't miss the complete list of biotech stocks to buy now.

And for more ways to profit, check out:

• The Best Cheap Stocks to Buy Now
• 5 Ways Twitter Can Make You a Better Trader

Biotech stock #6: Illumina (ILMN) originally appeared on BloggingStocks on Sun, 12 Jul 2009 15:00:00 EST. Please see our terms for use of feeds.

Cerus Corp. (NASDAQ: CERS) is a real company with real revenues, but no profits yet, and could be at a $50 million revenue run rate in 2010.

It is a pioneer in something called "pathogen inactivation" -- a technology that cleans blood, making blood banks almost completely indifferent to the health of donors. It's the perfect system in the age of AIDS, bird flu and other infectious disease. Cerus' INTERCEPT Blood System is currently sold in 18 countries, and a potential major catalyst is an expedited approval process in the United States.

The stock is trading around a buck -- down from nearly $8 about a year ago -- and it could be worth $10 in a couple of years.

Your best strategy for life-changing profits?

Buy the stock and wait. You may be waiting a while, but this is a solid company with a real product and profits, and stock appreciation should come in the next two years. Make that big-time appreciation.

Next: Biotech Stock #6

Biotech stock #5: Cerus Corp. (CERS) originally appeared on BloggingStocks on Sun, 12 Jul 2009 11:00:00 EST. Please see our terms for use of feeds.

Curis (NASDAQ: CRIS) is a speculative stock -- no approved product and no revenue -- that, in former markets, would sell for $10 - $12. It is now around a buck and a half, after doubling in the past few months.

CRIS focuses on cancer treatments, and is partnered with Genentech/Roche. It has a new therapy for basal cell carcinoma in mid-stage trials. The results appear very promising. In fact, they are so promising that Genentech is treating this as the last trial needed before seeking FDA approval.

This stock is a potential 10- to 20-bagger with an FDA approval in 2011 or so. And the company is on the verge of licensing a new molecule that could be a big catalyst for the stock in the short term.

Your best strategy for life-changing profits?

Buy CRIS now. (In the interest of full disclosure, I own a lot of CRIS.)

Next: Biotech Stock #5

Biotech stock #4: Curis (CRIS) originally appeared on BloggingStocks on Sun, 12 Jul 2009 09:00:00 EST. Please see our terms for use of feeds.

When my son had a huge boil under his arm, it turned out that it was filled with the killer staph, MRSA. It also turns out that my (otherwise) great doctor used a traditional lab to process the test, which took a week to determine it was MRSA.

Cepheid (NASDAQ: CPHD) manufactures the equipment and test that takes just two hours to do the same thing -- and is better and cheaper than traditional tests. CPHD wins 90%-plus of all competitive bids and its test could be available in low-tech facilities, such as doctor's offices or nursing homes, next year.

The big catalyst for this stock, however, is that Medicare will stop paying for all hospital-acquired infections except MRSA in October. So institutions need a quick test if they are going to be reimbursed for treatment.

The stock has fallen from $30 to under $9. It's worth $20 - $22 to an acquirer.

Your best strategy for life-changing profits?

Buy the call options.

Next: Biotech Stock #4

Continue reading Biotech stock #3: Cepheid (CPHD)

Biotech stock #3: Cepheid (CPHD) originally appeared on BloggingStocks on Sat, 11 Jul 2009 14:30:00 EST. Please see our terms for use of feeds.

Imagine a company with 90%-plus margins and huge cashflow that uses its cash to carefully expand its business and buy back stock -- with a P/E under 8! That's Questcor Pharmaceuticals (NASDAQ: QCOR).

QCOR has a treatment that is approved for spasms from multiple sclerosis, but is mostly used to treat radical infantile spasms that kill or retard babies.

Your best strategy for life-changing profits?

Buy the stock and wait for it to appreciate or for the company to get bought out. You could also buy the (illiquid) options, or buy the stock and sell the calls.

Next: Biotech Stock #3

Biotech stock #2: Questcor Pharmaceuticals (QCOR) originally appeared on BloggingStocks on Sat, 11 Jul 2009 13:00:00 EST. Please see our terms for use of feeds.